|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
These favorite names in the volatile sector offer the potential for high rewards.
Despite markets at record highs, companies are satisfying their appetites to grow and find value by buying others.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
Pfizer is making another acquisition.
It was nice to fill in for Doug Kass on what was a very uneventful Monday to begin the week. The market traded in an extremely narrow range for the day, and outside the strength in biotech and the weakness in oil after a nice recent rally there real...
Markets continue to trade in a very narrow range and remain largely directionless. Interesting story of the day: Distressed debt billionaire and investor Wilbur Ross buying hundreds of millions of dollars in distressed energy debt in a bid to take c...
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Stocks are back to flat to slightly lower overall, but biotechs are up some 1.5% following the announcement from Pfizer of plans to buy Medivation for $14 billion. Gilead Sciences is getting some flak for not pursuing Medivation more heavily, but I ...
Overall, this is still a good environment for stock picking.
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
A potential blockbuster drug deal is reportedly in the works.
The sector seems to be rebounding after tumbling by more than 40%.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
All of these add up to a level of insecurity on the part of sidelined money.
It's a pretty broad spectrum, but they've definitely arrived.
There are renewed worries about Brexit as the British pound has fallen to a new 30 year low.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.